A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Amir Hossein Daneshmanesh(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Amineh Ghaderi(Karolinska University Hospital), Ali Moshfegh(Karolinska University Hospital), Anders Österborg(Karolinska University Hospital), Lotta Hansson(Karolinska Institutet), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Jan Vågberg(Kancera (Sweden)), Elisabeth Olsson(Karolinska Institutet), Johan Schultz(Kancera (Sweden)), Styrbjörn Byström(Karolinska Institutet), Thomas Olin(Kancera (Sweden))
Cited by 43
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312